GlassScriptPhysician profile
Mariene Doukoure Balde
NPI 1114686847
$10,707.34
in general payments reported to CMS, 2019-2025
62 companies · $3,747 in 2025
The $3,747 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $196 · 2023: $2,438 · 2024: $4,327 · 2025: $3,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,767 · Long Term Medical Supply Or Device Loan: $881 · Education: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,767.35 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $863.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,687.08 | 2023-2025 | |
| Janssen Biotech, INC. | $991.04 | 2023-2025 | Darzalex, Erleada, Talvey |
| Celgene Corporation | $514.27 | 2023-2025 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $510.24 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $475.44 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Sobi, INC | $432.73 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.15 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Lilly USA, LLC | $394.59 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $383.43 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $332.44 | 2023-2025 | |
| Array Biopharma INC | $243.24 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Merck Sharp & Dohme LLC | $223.59 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $215.46 | 2023-2025 | |
| Pharmaessentia USA Corporation | $205.36 | 2024-2025 | Besremi |
| Gilead Sciences, INC. | $202.31 | 2023-2025 | Trodelvy |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $200.83 | 2022-2025 | |
| Astellas Pharma US INC | $195.19 | 2023-2024 | Xospata |
| Glaxosmithkline, LLC. | $194.65 | 2023-2025 | Zejula, Ojjaara, Jemperli |
| Rigel Pharmaceuticals, INC. | $181.78 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $173.35 | 2023-2025 | |
| Genentech USA, INC. | $154.81 | 2023-2025 | Polivy, Phesgo, Tecentriq Hybreza |
| Emd Serono, INC. | $150.23 | 2024-2025 | |
| Puma Biotechnology, INC. | $149.78 | 2023-2025 | Nerlynx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.64 | 2024-2025 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $125.12 | 2024-2025 | Libtayo |
| Daiichi Sankyo INC. | $125.02 | 2024-2025 | Enhertu, Datroway |
| Coherus Oncology, INC. | $118.39 | 2024-2025 | Loqtorzi |
| Seagen INC. | $111.66 | 2023 | Adcetris, Tukysa, Padcev |
| Karyopharm Therapeutics INC. | $110.40 | 2023-2025 | Xpovio |
| Genzyme Corporation | $89.97 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2022 | |
| Tempus Ai, INC | $75.56 | 2024 | |
| Aveo Pharmaceuticals, INC. | $75.33 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $74.88 | 2023-2025 | |
| Morphosys, US INC. | $70.67 | 2023-2024 | Monjuvi |
| Stemline Therapeutics INC. | $63.39 | 2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $63.34 | 2023-2025 | Pyrukynd |
| Novocure INC. | $61.80 | 2023-2025 | Optune Lua (Novottf-200t), Optune |
| Sumitomo Pharma America, INC. | $53.38 | 2023-2025 | Orgovyx |
| Beone Medicines USA, INC. | $53.08 | 2025 | Brukinsa |
| Genmab U.S., INC. | $51.77 | 2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $46.92 | 2023 | Imbruvica |
| Taiho Oncology, INC. | $45.09 | 2024 | |
| Pharmacosmos Therapeutics INC. | $36.82 | 2025 | Monoferric |
| Amgen INC. | $34.67 | 2022-2023 | Lumakras |
| Tersera Therapeutics LLC | $31.27 | 2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $26.03 | 2024 | Somatuline Depot, Onivyde |
| Progenics Pharmaceuticals, INC. | $25.23 | 2023 | Pylarify |
| Geron Corporation | $23.93 | 2025 | Rytelo |
| Amneal Pharmaceuticals LLC | $23.55 | 2023 | Avastin, Neupogen, Neulasta |
| Spectrum Pharmaceuticals INC. | $23.37 | 2025 | Rolvedon |
| Apellis Pharmaceuticals, INC. | $22.59 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $21.79 | 2024 | Poteligeo |
| Iovance Biotherapeutics, INC. | $21.73 | 2025 | Amtagvi |
| Blue Earth Diagnostics | $21.56 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.52 | 2023 | |
| Recordati_rare_diseases_inc. | $21.51 | 2023 | Sylvant |
| Deciphera Pharmaceuticals INC. | $18.57 | 2024 | Qinlock |
| Fresenius Kabi USA, LLC | $18.39 | 2025 | |
| Shield Therapeutics INC | $17.91 | 2025 | |
| Caris Mpi, INC. | $17.38 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $13.12 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariene Doukoure Balde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.